Message Font: Serif | Sans-Serif
No. of Recommendations: 0
A load of good news lately from the self-described leading genomic information company.

Exclusive antibody agreement with Genentech..."Incyte Genomics Signs Exclusive Patent Agreement With Genentech to Enable Commercialization of Therapeutic Antibodies to Four Proteins"

Agreement with Medarex for codevelopment of antibody drugs. "Medarex and Incyte Genomics Announce Partnership to Develop and Commercialize Fully Human Antibody Therapeutics. Partnership Will Leverage Incyte's Industry Leading Commercial Portfolio Of Patented Full-Length Genes, Proteins and Antibodies With Medarex's Human Antibody Technology"

A small victory in the litigation front with Affymetrix. "District Court for the Northern District of California has granted a victory to Incyte by issuing a summary judgment ruling on October 3, 2001 in favor of Incyte for the remaining two disputed claims of the ``two-color' patent presently issued to Affymetrix. Over the past few months, there have been several recent summary judgment decisions in its patent litigation with Affymetrix, Inc. (Nasdaq: AFFX - news). Two of those decisions invalidate certain patent claims that Affymetrix has asserted against Incyte, and another holds that Incyte's commercially-available cDNA microarrays do not infringe other Affymetrix patent claims."

Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.